AMMAN —
Hikma Pharmaceuticals signed a licensing agreement
with the
Medicines Patent Pool (MPP) to manufacture and market Molnupiravir, an
oral antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults, , according to the Jordan News Agency, Petra.
اضافة اعلان
In a statement on Thursday, the company said that the agreement aims at
enhancing patients' access to one of the most important drugs used to treat the
coronavirus, developed by Merck, an American multinational pharmaceutical
company, and to place it on the markets of the Middle East and North Africa.
Under the agreement, Hikma has the rights to use Merck's patents and
manufacturing expertise for the drug, and is responsible for manufacturing and
marketing the product in 105 low- and middle-income countries in the Middle
East.
Executive Vice Chairman and President of Hikma in the Middle East and North
Africa
Mazen Darwazah said that the agreement comes in line with the company's
mission to provide better health for all, and to facilitate the access for
Molnupiravir use in low- and middle-income countries.
The agreement, he explained, reflects Hikma's ongoing commitment to improving
access to high-quality and affordable treatments, adding that the company is
"looking forward to providing and enabling patients to use this treatment
soon."
Read more Business
.jpg)
.jpg)
